Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report

被引：2
|
作者：
Pang, Hua-Yang [1 ,2 ]
Yan, Meng-Yua [1 ]
Chen, Xiu-Feng [1 ]
Sun, Hao [1 ]
机构：
[1] Chongqing Univ, Canc Hosp, Dept Gastrointestinal Canc Ctr, Chongqing 400030, Peoples R China
[2] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing 400030, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2025年 / 48卷 / 01期
关键词：
D O I：
10.1016/j.asjsur.2024.07.136
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：759 / 761
页数：3
相关论文
共 50 条
  • [41] Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer
    He, Qifei
    Chen, Jiahui
    Zhou, Kai
    Jin, Chenggen
    Wang, Anqiang
    Ji, Ke
    Ji, Xin
    Zhang, Ji
    Wu, Xiaojiang
    Li, Xia
    Bu, Zhaode
    Ji, Jiafu
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) : 4413 - 4422
  • [42] HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report
    Longo, Raffaele
    Legros, Pierre-Olivier
    Talbi, Marouane
    Wagner, Marc
    Paraschiv, Elena-Adinisia
    Campitiello, Marco
    Plastino, Francesca
    Rozzi, Antonio
    CLINICAL CASE REPORTS, 2020, 8 (12): : 2877 - 2881
  • [43] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Pier Paolo M. Berton Giachetti
    Giuseppe Curigliano
    Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
  • [44] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [45] Trastuzumab in HER2-Positive Metastatic Gastric CancerProfile Report
    Jamie D. Croxtall
    Kate McKeage
    BioDrugs, 2011, 25 : 257 - 259
  • [46] Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
    McCormack, Paul L.
    DRUGS, 2013, 73 (13) : 1491 - 1502
  • [47] Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
    Paul L. McCormack
    Drugs, 2013, 73 : 1491 - 1502
  • [48] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    Tsang, R. Y.
    Finn, R. S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
  • [49] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    R S Finn
    British Journal of Cancer, 2012, 106 : 6 - 13
  • [50] Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sallt
    Button, Peter
    Devitt, Bianca
    Forster, Benjamin
    Fox, Peter
    Harold, Michael
    Ketheeswaran, Sahisha
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    CANCER RESEARCH, 2022, 82 (04)
12345